title: Clinical trials using irinotecan.
authors: Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
authors: Peter J
authors: PJ
authors: Houghton
authors: Victor M
authors: VM
authors: Santana
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D019457:Chromosome Breakage; D002986:Clinical Trials as Topic; D004249:DNA Damage; D004261:DNA Replication / Q000187:drug effects; D004264:DNA Topoisomerases, Type I / Q000378:metabolism; D004273:DNA, Neoplasm / Q000187:drug effects*; D004334:Drug Administration Schedule; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D000077146:Irinotecan; D051379:Mice; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors*; D009447:Neuroblastoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D012208:Rhabdomyosarcoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics; D059004:Topoisomerase I Inhibitors; D019772:Topotecan / Q000494:pharmacology / Q000627:therapeutic use; D023041:Xenograft Model Antitumor Assays
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D004273:DNA, Neoplasm; D004791:Enzyme Inhibitors; D009363:Neoplasm Proteins; D059004:Topoisomerase I Inhibitors; D000077146:Irinotecan; D019772:Topotecan; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin